FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149477575> ?p ?o ?g. }

• W2149477575 endingPage "2265" @default.
• W2149477575 startingPage "2264" @default.
• W2149477575 abstract "A potential role for lipoxygenase (LO) products and reactive oxygen species (ROS) in mouse B-lymphocyte activation and differentiation was investigated. Previously published investigations with the nonspecific 5-LO (EC 1.13.11.34) and 12-LO (EC 1.13.11.31) inhibitors such as nordihydroguaiaretic acid (NDGA) and 6,7-dihydroxycoumarin (Esculetin), are misleading in that they suggest lymphocyte LO activity is required for activation and differentiation of these cells. In initial support of this concept, we report that NDGA and Esculetin completely inhibited B-lymphocyte activation mediated by either membrane immunoglobulin (mlg), or the lipopolysaccharide (LPS) receptor. NDGA and Esculetin completely inhibited cell enlargement and proliferation, exhibiting half maximal inhibitory concentrations (IC50S) of approximately 1 × 10−6 M. In contrast, the highly specific 5-LO inhibitors BAY X 1005, MK-886 and Wy 50,295 did not inhibit cell enlargement or proliferation. Moreover, 5,8,11-eicosatriynoic acid (ETI) which inhibits 5- and 12-LO, and 5, 8, 11, 14-eicosatetraynoic acid (ETYA) which inhibits all known LOs did not affect B-lymphocyte proliferation. Interestingly, NDGA and Esculetin are antioxidants, unlike BAY X 1005, MK-886, Wy 50,295, ETI and ETYA. Our hypothesis was that the antioxidant activities of NDGA and Esculetin were responsible for inhibiting B-lymphocyte activation and proliferation and we speculated that ROS and not LO activity was required for both processes. Additional antioxidants such as butylated hydroxy toluene, o-phenanthroline, thiourea, and α-tocopherol (vitamin E), also inhibited B-lymphocyte proliferation induced by either the LPS or mIg receptors. These agents exhibited IC50s of 1 × 10−8 M, 5 × 10−10 M, 6 × 10−3 M and 5 × 10−5 M, respectively. When resting B-lymphocytes were treated with a source of ROS (1 × 10−5 M H2O2), cells enlarged in a temperature-sensitive manner, which is similar to LPS-induced enlargement. Both NDGA and Esculetin completely inhibited H2O2-induced enlargement. These results further indicate that ROS are required for B-lymphocyte activation and proliferation. Similar results were obtained for B-lymphocyte differentiation. NDGA and Esculetin completely inhibited the development of plasma cells and displayed IC50S of 5 × 10−6 M. Conversely, BAY X 1005, MK-886, Wy 50,295, ETI, and ETYA did not block the formation of plasma cells. Therefore, ROS are also crucial for differentiation into plasma cells. These experiments are the first to directly illustrate that intracellular ROS mediate B-lymphocyte activation, proliferation and differentiation and that LO products are not required for these processes. Moreover, this investigation ilustrates that NDGA and Esculetin are not specific LO inhibitors and that their use cannot implicate a role for LO activity." @default.
• W2149477575 created "2016-06-24" @default.
• W2149477575 creator A5050938468 @default.
• W2149477575 creator A5054342480 @default.
• W2149477575 creator A5062540623 @default.
• W2149477575 creator A5062716750 @default.
• W2149477575 creator A5075065772 @default.
• W2149477575 date "1990-07-01" @default.
• W2149477575 modified "2023-09-25" @default.
• W2149477575 title "Biological activities of CO/I828, a novel topical antiinflammatory agent" @default.
• W2149477575 doi "https://doi.org/10.1016/0014-2999(90)93807-3" @default.
• W2149477575 hasPublicationYear "1990" @default.
• W2149477575 type Work @default.
• W2149477575 sameAs 2149477575 @default.
• W2149477575 citedByCount "1" @default.
• W2149477575 crossrefType "journal-article" @default.
• W2149477575 hasAuthorship W2149477575A5050938468 @default.
• W2149477575 hasAuthorship W2149477575A5054342480 @default.
• W2149477575 hasAuthorship W2149477575A5062540623 @default.
• W2149477575 hasAuthorship W2149477575A5062716750 @default.
• W2149477575 hasAuthorship W2149477575A5075065772 @default.
• W2149477575 hasConcept C181199279 @default.
• W2149477575 hasConcept C185592680 @default.
• W2149477575 hasConcept C2776889390 @default.
• W2149477575 hasConcept C2778004101 @default.
• W2149477575 hasConcept C2780857362 @default.
• W2149477575 hasConcept C48349386 @default.
• W2149477575 hasConcept C55493867 @default.
• W2149477575 hasConcept C62112901 @default.
• W2149477575 hasConcept C86803240 @default.
• W2149477575 hasConcept C98274493 @default.
• W2149477575 hasConceptScore W2149477575C181199279 @default.
• W2149477575 hasConceptScore W2149477575C185592680 @default.
• W2149477575 hasConceptScore W2149477575C2776889390 @default.
• W2149477575 hasConceptScore W2149477575C2778004101 @default.
• W2149477575 hasConceptScore W2149477575C2780857362 @default.
• W2149477575 hasConceptScore W2149477575C48349386 @default.
• W2149477575 hasConceptScore W2149477575C55493867 @default.
• W2149477575 hasConceptScore W2149477575C62112901 @default.
• W2149477575 hasConceptScore W2149477575C86803240 @default.
• W2149477575 hasConceptScore W2149477575C98274493 @default.
• W2149477575 hasIssue "6" @default.
• W2149477575 hasLocation W21494775751 @default.
• W2149477575 hasOpenAccess W2149477575 @default.
• W2149477575 hasPrimaryLocation W21494775751 @default.
• W2149477575 hasRelatedWork W1991451399 @default.
• W2149477575 hasRelatedWork W2013119187 @default.
• W2149477575 hasRelatedWork W2022162405 @default.
• W2149477575 hasRelatedWork W2039396482 @default.
• W2149477575 hasRelatedWork W2051745045 @default.
• W2149477575 hasRelatedWork W2068023029 @default.
• W2149477575 hasRelatedWork W2166866654 @default.
• W2149477575 hasRelatedWork W2187986244 @default.
• W2149477575 hasRelatedWork W2354457077 @default.
• W2149477575 hasRelatedWork W2397581323 @default.
• W2149477575 hasVolume "183" @default.
• W2149477575 isParatext "false" @default.
• W2149477575 isRetracted "false" @default.
• W2149477575 magId "2149477575" @default.
• W2149477575 workType "article" @default.